The proposed bill aims to enhance patient access to discounted medications and health care services in Washington by safeguarding the 340B drug pricing program from manufacturer-imposed limitations. The 340B program is crucial for providing affordable medications to low-income and uninsured populations through eligible health care providers, including federally qualified health centers and safety net hospitals. The bill prohibits drug manufacturers and their representatives from denying or restricting the acquisition and delivery of 340B drugs to covered entities and their contracted pharmacies. It also prevents manufacturers from requiring covered entities to submit claims or data as a condition for accessing these drugs, unless mandated by federal law.

Additionally, the bill establishes penalties for violations, allowing covered entities to file civil actions against manufacturers for non-compliance, with potential fines of up to $5,000 per day for each violation. The Attorney General is also empowered to enforce these provisions on behalf of the state. Furthermore, hospital covered entities are required to report annually on their participation in the 340B program, detailing how they utilize savings to benefit their communities. The Department of Health will oversee this reporting and may impose fines for non-compliance. The bill includes provisions to ensure its compatibility with federal law and outlines that if specific funding is not provided by June 30, 2026, the act will become null and void.